McCollum Christoferson Group LLC Sells 220 Shares of STERIS plc (NYSE:STE)

McCollum Christoferson Group LLC trimmed its holdings in shares of STERIS plc (NYSE:STE) by 0.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 32,395 shares of the medical equipment provider’s stock after selling 220 shares during the quarter. STERIS comprises about 2.3% of McCollum Christoferson Group LLC’s investment portfolio, making the stock its 22nd largest holding. McCollum Christoferson Group LLC’s holdings in STERIS were worth $7,857,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Central Pacific Bank Trust Division acquired a new stake in STERIS during the third quarter worth about $28,000. J.Safra Asset Management Corp grew its stake in STERIS by 77.9% during the first quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 53 shares in the last quarter. Quent Capital LLC grew its stake in STERIS by 112.7% during the first quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 71 shares in the last quarter. Headlands Technologies LLC acquired a new stake in STERIS during the first quarter worth about $36,000. Finally, Versant Capital Management Inc grew its stake in STERIS by 2,262.5% during the second quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock worth $41,000 after buying an additional 181 shares in the last quarter. 94.69% of the stock is owned by institutional investors.

STERIS Trading Down 0.3 %

STE opened at $225.99 on Thursday. The company’s 50 day moving average is $236.16 and its 200-day moving average is $225.91. STERIS plc has a 1-year low of $195.47 and a 1-year high of $248.24. The company has a current ratio of 2.33, a quick ratio of 1.49 and a debt-to-equity ratio of 0.35. The company has a market cap of $22.29 billion, a P/E ratio of 56.08 and a beta of 0.84.

STERIS (NYSE:STE) last posted its earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping the consensus estimate of $1.98 by $0.16. STERIS had a net margin of 7.36% and a return on equity of 13.85%. The business had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same period last year, the company earned $2.00 EPS. The firm’s revenue was down .4% compared to the same quarter last year. Equities research analysts predict that STERIS plc will post 9.06 earnings per share for the current fiscal year.

STERIS Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 20th. Investors of record on Thursday, September 5th were given a dividend of $0.57 per share. The ex-dividend date of this dividend was Thursday, September 5th. This is an increase from STERIS’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a yield of 1.01%. STERIS’s dividend payout ratio (DPR) is currently 56.58%.

Insider Buying and Selling

In related news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the sale, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other STERIS news, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the transaction, the director now owns 582 shares in the company, valued at approximately $139,493.76. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Michael J. Tokich sold 23,332 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the transaction, the chief financial officer now owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on STE shares. KeyCorp increased their price objective on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 3rd. Stephens reiterated an “overweight” rating and set a $260.00 price objective on shares of STERIS in a research note on Wednesday, August 7th. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. JMP Securities restated a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a research note on Wednesday, August 7th. Finally, StockNews.com upgraded shares of STERIS from a “hold” rating to a “buy” rating in a research note on Tuesday, August 13th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $246.00.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.